ImmuneRegen BioSciences, Inc. Announces First Study Of Viprovex(TM) To Explore Adjuvant Capabilities In The Area Of Pandemic Influenza Vaccine

ImmuneRegen
BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc.
(OTC Bulletin Board: IRBO), today announced it has commenced the first
study of Viprovex(TM) to explore its adjuvant capabilities in the area of
Pandemic Influenza Vaccine. The study is being conducted in conjunction
with privately-held vaccine developer GenPhar, Inc., of Charleston, SC.
GenPhar began its biodefense program in 2000 as one of the first in the
industry and now works closely with the Department of Defense. GenPhar has
vaccines for lethal viruses such as Ebola, Marburg, dengue and influenza,
with several approaching the final development and testing stages prior to
approval.


"We are very happy to announce our relationship with GenPhar which has
developed a promising portfolio of vaccines and are excited to begin
generating data in this very relevant area. If we can confirm
immunostimulatory adjuvant activity in conjunction with an effective
vaccine against Avian Influenza, we can help vaccinate many more Americans
helping limited amounts of vaccine provide more effective, perhaps global
coverage," said ImmuneRegen's CEO Michael Wilhelm. "GenPhar's vaccine
development program is aggressively achieving milestones against viruses
such as HIV, hepatitis B and C virus, influenza, and potential bioterror
agents such as the hemorrhagic fevers caused by Ebola and Marburg virus,
and dengue fever. We are very pleased to be working with such a
well-established and respected scientific team, and believe that positive
results with Viprovex(TM) will also open up the possibilities to include
Viprovex(TM) into other vaccines against diseases with great social and
economical impacts, such as HIV and hepatitis C and can be followed up with
additional studies further demonstrating adjuvant capabilities."



About Radilex and Viprovex



Radilex is the trade name used in referring to formulations of Homspera
for potential indications for treatment of exposure to ionizing radiation.
Viprovex is the trade name used in referring to formulations of Homspera
for potential indications for treatment of viral and bacterial infections.
Homspera is a generic name used by the Company to describe the synthetic
peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an
analog of the naturally occurring human neuropeptide Substance P, which can
be found throughout the body, including in the airways of humans and many
other species. All of the Company's research and development efforts are
early, pre-clinical stage and Homspera, as Viprovex and Radilex, has only
undergone exploratory studies to evaluate its biological activity in small
animals.
















About ImmuneRegen BioSciences, Inc.



IR BioSciences Holdings Inc., through its wholly owned subsidiary
ImmuneRegen BioSciences, Inc., is a development stage biotechnology company
focused on the research and development of Homspera(TM) and its derivatives
Radilex(TM) and Viprovex(TM), which are under study as candidate
therapeutic countermeasures for multiple homeland security bioterrorism
threats. Homspera is derived from Substance P, a naturally occurring
peptide immunomodulator. For more information, please visit the company's
website at immuneregen.



About GenPhar, Inc.



GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a
leader in developing and producing prophylactic and therapeutic vaccines to
protect against the world's most dangerous diseases. To reach its goals,
GenPhar will leverage the advantage of its proven safe and effective ProVax
and TheraVax vaccine platforms -- unique technology capable of producing
multiple vaccine products. GenPhar's products are divided into two main
areas: vaccines for biodefense and vaccines for chronic infectious diseases
(including HIV, hepatitis B and hepatitis C). These products will have a
large scale socio-economic impact and transformative effect on current
research and treatments. GenPhar was founded in 1999 and is headquartered
in Mount Pleasant, South Carolina.



Statements about the Company's future expectations, including
statements about the potential for the Company's drug candidates, science
and technology, and all other statements in this press release other than
historical facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created thereby.
These future events may not occur as and when expected, if at all, and,
together with the Company's business, are subject to various risks and
uncertainties. The Company's actual results could differ materially from
expected results as a result of a number of factors, including the fact
that preliminary results involved only a small number of test mice, the
subsequent investigations were limited in scope, the uncertainties inherent
in research and development collaborations, pre-clinical and clinical
trials and product development programs, (including, but not limited to the
fact that future results or research and development efforts may prove less
encouraging than current results or cause side effects not observed in
current pre-clinical trials) the evaluation of potential opportunities, the
level of corporate expenditures and monies available for further studies,
capital market conditions, and others set forth in the Company's periodic
report on Form 10-QSB for the three months ended September 30, 2006 and on
Form 10-KSB for the twelve months ended December 31, 2005 as filed with the
Securities and Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially successful. The
Company undertakes no duty to update forward-looking statements.


ImmuneRegen BioSciences, Inc.

immuneregen